Elesclomol and Paclitaxel Combo: A Missed Opportunity in Ovarian Cancer Treatment?
"A recent study evaluates the effectiveness of combining elesclomol sodium with weekly paclitaxel for recurrent ovarian cancer. Discover the results and what they mean for future treatments."
Recurrent epithelial ovarian, primary peritoneal, and fallopian tube cancer (EOC) presents significant treatment challenges once platinum-based therapies become ineffective. After initial platinum treatment, typically single-agent chemotherapy, such as liposomal doxorubicin or topotecan, has been the standard when the platinum-free interval (PFI) is less than six months. For longer intervals, doublet chemotherapy is preferred.
For decades, the Gynecologic Oncology Group (GOG) has been at the forefront, seeking innovative solutions for recurrent ovarian cancer. Historically, only a few agents have demonstrated overall response rates (ORR) exceeding 20% in platinum-resistant cases. This reality underscores the urgent need for novel treatments to improve outcomes in recurrent EOC.
Elesclomol, known as STA-4783, is a novel molecule that enhances oxidative stress within cancer cells, potentially increasing their sensitivity to chemotherapy. Preclinical data suggested synergistic anti-tumor activity when combined with paclitaxel. Building on these findings, a phase 2 trial was initiated to explore the clinical benefits of elesclomol in combination with paclitaxel for recurrent ovarian cancer.
Clinical Need and Trial Focus
The CDC reports that ovarian cancer is the second most common gynecologic cancer in the United States and causes more deaths than any other cancer of the female reproductive system. Clinical trial NCT00888615 evaluated elesclomol sodium with paclitaxel in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer. A prospective multicenter phase II trial similarly assessed intravenous elesclomol plus weekly paclitaxel in platinum-resistant recurrent ovarian, tubal, or peritoneal cancer, using objective tumor response as the primary measure of activity.
From Late Diagnosis to Molecular Insight
Ovarian cancer has been called a “silent killer” because inapparent tumor growth, delayed symptoms, inadequate screening, and nonspecific symptoms often contribute to diagnosis at an advanced stage. Research into ovarian-cancer origins has examined histogenesis and used genomic and proteomic profiling to model early carcinogenesis. Identifying the origins of precancerous lesions is especially important because ovarian cancer is located deep in the pelvis and is not amenable to routine cancer screening or primary prevention. Historically, treatment included surgery and melphalan chemotherapy; in 1976, cisplatin replaced melphalan, while only 18% of women diagnosed with ovarian cancer in the 1970s lived for 10 years or more.
Elesclomol's Mechanism and Clinical Trial Results
Elesclomol functions by binding to copper ions in the bloodstream, allowing it to be efficiently taken up by cancer cells. Once inside, it promotes a redox reaction that increases reactive oxygen species (ROS) and oxidative stress. This mechanism is intended to disrupt mitochondrial metabolism, leading to cancer cell death while sparing normal cells.
- Study Design: A prospective, multicenter phase 2 trial.
- Participants: Patients with measurable disease, acceptable organ function, performance status ≤ 2, and one prior platinum-containing regimen.
- Treatment: Elesclomol plus weekly paclitaxel.
- Objectives: To estimate the objective response rate (ORR) and assess toxicity.
Clinical Results and Delivery Challenges
A review of cancer chemotherapy regimens records paclitaxel at 80 mg/m2 and elesclomol sodium at 200 mg/m2 as separate one-hour intravenous infusions given weekly for three weeks, followed by a one-week rest. A review of cuproplasia and cuproptosis reports a 19.6% response rate, median progression-free survival of 3.6 months, and median overall survival of 13.3 months for the combination in ovarian, fallopian tube, or primary peritoneal cancer. That review states these outcomes were not better than typical outcomes with paclitaxel alone in this setting, although the combination was well tolerated. Other recent work has focused on elesclomol's short systemic half-life and nanoparticle delivery strategies intended to improve therapeutic efficacy.
Limited Benefit in Unselected Patients
In advanced melanoma, adding elesclomol to paclitaxel did not significantly improve progression-free survival in unselected patients. A prospectively defined subgroup analysis did find a statistically significant improvement in median progression-free survival among patients with normal baseline LDH. In the ovarian-cancer study identified as NCT00888615, the combination was reported as well tolerated, with no grade 4 toxicities, but the investigators concluded that it was unworthy of further investigation based on the proportion responding.
A Small Evaluated Cohort
The cited study on nausea prophylaxis enrolled 43 patients. Of those patients, 40 were evaluable for response. The source snippet provides the enrollment and evaluability figures but does not report comparative efficacy results for elesclomol and paclitaxel.
Study Implications and Future Directions
Though preclinical models showed promise, this phase 2 trial found no added clinical benefit in terms of ORR when elesclomol was combined with weekly paclitaxel for platinum-resistant recurrent EOC. The study highlights the ongoing challenges in translating preclinical success to clinical efficacy, reminding us that factors such as drug resistance, immune surveillance, drug delivery, and the tumor microenvironment play critical roles.
Biomarkers and Emerging Strategies
A 2026 review describes ovarian cancer as the eighth leading cause of cancer deaths in women globally and notes that it mainly originates from epithelial cells. It categorizes ovarian cancer into type I and type II according to histologic, molecular, clinical, and epidemiological characteristics. The review also reports that ovarian cancer is commonly diagnosed in postmenopausal women, although this varies by ethnicity and genetics. Current treatment updates emphasize guideline changes, clinical-trial data, and emerging biomarkers.
Target Validation and Future Research
A comparative guide to elesclomol sodium examines its performance against other therapeutic alternatives in specific cancer types. The guide is based on experimental data and addresses the compound's mechanism of action and target validation. It also presents detailed experimental protocols intended to support the evaluation and design of future research.